Session » Abstracts: RA – Treatments II: RA Treatment Safety
- 4:00PM-5:30PM
-
Abstract Number: 1678
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis
- 4:00PM-5:30PM
-
Abstract Number: 1679
Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
- 4:00PM-5:30PM
-
Abstract Number: 1675
Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors
- 4:00PM-5:30PM
-
Abstract Number: 1676
Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
- 4:00PM-5:30PM
-
Abstract Number: 1677
Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
- 4:00PM-5:30PM
-
Abstract Number: 1680
What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?